Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with leishmania infantum

Journal of Infection

Volumn 40, Issue 2, 2000, Pages 199-202

  Ridolfo, A L ^a   Gervasoni, C ^a   Antinori, S ^a   Pizzuto, M ^a   Santambrogio, S ^a   Trabattoni, D ^a   Clerici, M ^a   Galli, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; INDINAVIR; LAMIVUDINE; MEGLUMINE ANTIMONATE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; LEISHMANIA INFANTUM; RASH; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

EID: 0034025456     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.1999.0630     Document Type: Article

References (19)

1. Alvar J, Canavate C, Gutierrez-Solar B. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 10:1997;298-319.
2. World Health Organization. Report on the consultative meeting on Leishmania /HIV co-infection. WHO/LEISH/95.35.Geneva, Switzerland, World Health Organization,1995;1-14.
3. Girla HS, Marsden RA, Singli GM. Post-kala-azar dermal leishmaniasis. Br J Dermatol. 39:1977;307-311.
4. Zijlstra EE, El-Hassam AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg. 52:1995;299-305.
5. Desjeux P. Leishmaniasis: public aspects and control. Clin Dermatol. 14:1996;417-423.
6. Moral L. Post-kala-azar dermal leishmaniasis and Leishmania infantum. Br J Dermatol. 140:1999;760.
7. Rios-Buceta L, Buezo GF, Penas PF. Post-kala-azar dermal leishmaniasis in an HIV-patient. Intern J Dermatol. 35:1996;303-304.
8. Meroni L, Trabattoni D, Balotta C. Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS. 10:1996;23-30.
9. Wolday D, Berhe N, Akuffo H, Britten S. Leishmania-HIV interaction: immunopathogenetic mechanism. Parasitol Today. 15:1999;182-187.
10. Ghalib HW, Piuvezam MR, Skelky YAW. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest. 92:1993;324-329.
11. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, de Sousa A. Potential role for interleukin 10 in the immune suppression associated with kala-azar. J Clin Invest. 92:1993;2626-2632.
12. Clerici M, Shearer M. Th1-Th2 switch is a critical step in the aetiology of HIV infection. Immunol Today. 14:1993;107-111.
13. Lopez-Velez R, Perez-Molina JA, Guerrero A. Clinicoepidemiologic characteristics, prognostic factors and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 58:1998;436-443.
14. Gradoni L, Gramiccia M. Leishmania infantum tropism: strain genotype or host immune status? Parasitol Today. 10:1994;264-267.
15. Laguna F, L óé R, Pulido F. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS. 13:1999;1063-1069.
16. Kenney RT, Sacks DL, Gam AA. Splenic cytokine response in Indian kala-azar before and after treatment. J Infect Dis. 177:1998;815-819.
17. Autran B, Carcelain T, Li TS. Positive effects of combined antiretroviral therapy on C4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
18. Race EM, Adelson-Mitty J, Kriegel GR. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 351:1998;252-255.
19. Karavellas MP, Lowder CY, Macdonald C. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol. 116:1998;169-175.